GLP-1 receptor agonist combined with pancreatic lipase inhibitor

This page covers all GLP-1 receptor agonist combined with pancreatic lipase inhibitor drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting GLP-1 receptor (liraglutide); pancreatic and gastric lipases (orlistat).

Targets

GLP-1 receptor (liraglutide); pancreatic and gastric lipases (orlistat)

Marketed (1)

• liraglutide combined with orlistat · The Fourth Affiliated Hospital of Zhejiang University School of Medicine · Endocrinology / Obesity
  Liraglutide stimulates GLP-1 receptors to increase insulin secretion and reduce appetite, while orlistat inhibits pancreatic lipase to reduce dietary fat absorption.

Patent intelligence

• glp 1 receptor agonist combined with pancreatic lipase inhibitor patent landscape — aggregated cliff calendar, attackable patents, originator estates